Levosimendan

Levosimendan, the (R)-enantiomer of simendan, is a pyridazinone-derivative calcium sensitizer and positive inotropic agent developed by Orion Corporation (Finland) and approved in approximately 60 countries for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy is not considered adequate. The compound exerts its principal pharmacological effects through three complementary mechanisms: calcium-dependent binding to the N-terminal domain of cardiac troponin C, which stabilizes the calcium-troponin C interaction and enhances myofilament sensitivity to calcium without increasing intracellular calcium concentration; selective inhibition of phosphodiesterase III (PDE3) in cardiac and vascular smooth muscle, which elevates cyclic adenosine monophosphate and contributes to positive inotropy and vasodilation; and opening of ATP-sensitive potassium channels (both sarcolemmal and mitochondrial) in vascular smooth muscle and cardiomyocytes, producing peripheral and coronary vasodilation and conferring cardioprotective effects against ischemia-reperfusion injury. The composite pharmacology produces the characteristic inodilator profile: simultaneous enhancement of cardiac contractility, reduction of cardiac preload and afterload, and improvement in coronary perfusion, all achieved without a proportional increase in myocardial oxygen demand.

The pharmacokinetic profile of levosimendan is distinguished by the formation of an active metabolite, OR-1896, through intestinal reduction of the parent compound to the amino-derivative OR-1855 followed by hepatic N-acetylation. OR-1896 exhibits calcium-sensitizing and PDE3-inhibitory activity comparable to the parent compound and possesses an elimination half-life of approximately 75 to 80 hours in heart failure patients, compared to approximately 1 hour for the parent. This metabolite formation pathway introduces N-acetyltransferase 2 (NAT2) acetylator phenotype as a determinant of OR-1896 exposure, with slow acetylators demonstrating lower OR-1896 concentrations and potentially diminished sustained hemodynamic effects. The prolonged activity of OR-1896 sustains hemodynamic improvement for 7 to 9 days following cessation of a standard 24-hour intravenous infusion, a property unique among clinically available inotropic agents.

The clinical evidence base comprises six principal Phase II and Phase III randomized controlled trials (LIDO, RUSSLAN, CASINO, REVIVE-I, REVIVE-II, SURVIVE) enrolling more than 3,000 patients with acute decompensated heart failure, supplemented by extensive registry data, meta-analyses, and ongoing investigation in cardiac surgery, cardiogenic shock, septic cardiomyopathy, pulmonary hypertension, right ventricular failure, and advanced heart failure with intermittent ambulatory infusion protocols. The LIDO trial demonstrated hemodynamic superiority and a 31-day survival advantage over dobutamine. The SURVIVE trial, the largest randomized comparison (1,327 patients), demonstrated superior reduction in B-type natriuretic peptide but did not achieve the primary endpoint of reduced 180-day all-cause mortality compared to dobutamine, though subgroup analyses favored levosimendan in patients on chronic beta-blocker therapy and those with prior heart failure history. Levosimendan is marketed as Simdax (Orion Corporation) and is not approved by the United States Food and Drug Administration; the original new drug application was withdrawn in 1999 following a request for additional trials. This monograph reviews the chemistry and stereochemistry, the triple-mechanism molecular pharmacology, the unique metabolite-driven pharmacokinetic profile, the comprehensive clinical evidence base, sourcing considerations, reconstitution and handling, drug interactions, adverse events, and a comparative assessment against five alternative inotropic agents on five competency standards.